SAN DIEGO, Aug, 3, 2021
/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS),
a biopharmaceutical company focused on the discovery and
development of innovative medicines targeting microRNAs (the
"Company" or "Regulus"), today announced that it will report
financial results and highlights for the quarter ended June 30, 2021 on Tuesday,
August 10, 2021, after the U.S. financial markets
close.
The Company will host a conference call and live audio webcast
on Tuesday, August 10, 2021 at
5:00 p.m. Eastern Daylight Time to
report its second quarter 2021 financial results and provide a
corporate update. To access the call, please dial (877)
257-8599 (domestic) or (970) 315-0459 (international) and refer to
conference ID 2825907. To access the telephone replay of the
call, dial (855) 859-2056 (domestic) or (404) 537-3406
(international), passcode ID 2825907. The webcast and
telephone replay will be archived on the Company's website at
www.regulusrx.com following the call.
Wedbush PacGrow Healthcare Conference
Additionally, the Company announced that Jay Hagan, President and Chief Executive
Officer, will participate in a panel at the 2021 Wedbush PacGrow
Healthcare Conference on Wednesday, August
11, 2021, at 4:05 p.m.
E.T.
A live webcast of the panel will be available on the investor
relations section of the Company's website at www.regulusrx.com. A
replay of the webcast will be archived for 30 days following the
presentation date.
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical
company focused on the discovery and development of innovative
medicines targeting microRNAs. Regulus has leveraged its
oligonucleotide drug discovery and development expertise to develop
a pipeline complemented by a rich intellectual property estate in
the microRNA field. Regulus maintains its corporate
headquarters in San Diego,
CA.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements associated with the clinical
activities concerning the RGLS4326 program, including the
preliminary biomarker, pharmacokinetic and safety data resulting
from the first cohort of patients from the ongoing clinical study,
the sufficiency of the data required to recommence clinical studies
for extended duration dosing, the timing of the Company's
interactions with FDA regarding the clinical hold, the timing and
of other preclinical and clinical activities and the Company's
expected cash runway. Because such statements are subject to
risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking statements.
Words such as "believes," "anticipates," "plans," "expects,"
"intends," "will," "goal," "potential" and similar expressions are
intended to identify forward-looking statements. These
forward-looking statements are based upon Regulus' current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results and the timing of
events could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, which include, without limitation, risks associated
with the process of discovering, developing and commercializing
drugs that are safe and effective for use as human therapeutics and
in the endeavor of building a business around such drugs, and
feedback from the FDA. In addition, while Regulus expects the
COVID-19 pandemic to adversely affect its business operations and
financial results, the extent of the impact on Regulus' ability to
achieve its preclinical and clinical development objectives and the
value of and market for its common stock, will depend on future
developments that are highly uncertain and cannot be predicted with
confidence at this time, such as the ultimate duration of the
pandemic, travel restrictions, quarantines, social distancing and
business closure requirements in the U.S. and in other countries,
and the effectiveness of actions taken globally to contain and
treat the disease. These and other risks are described
in additional detail in Regulus' filings with the Securities and
Exchange Commission. All forward-looking statements contained
in this press release speak only as of the date on which they were
made. Regulus undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regulus-therapeutics-announces-timing-for-second-quarter-2021-financial-results-webcast-and-conference-call-301347375.html
SOURCE Regulus Therapeutics Inc.